In:
PLOS ONE, Public Library of Science (PLoS), Vol. 15, No. 11 ( 2020-11-18), p. e0241739-
Abstract:
Due to the challenges for developing vaccines in devastating pandemic situations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), developing and screening of novel antiviral agents are peremptorily demanded. Herein, we developed EGYVIR as a potent immunomodulatory herbal extract with promising antiviral activity against SARS-CoV-2. It constitutes of a combination of black pepper extract with curcumin extract. The antiviral effect of EGYVIR extract is attributed to the two key phases of the disease in severe cases. First, the inhibition of the nuclear translocation of NF-kβ p50, attenuating the SARS-CoV-2 infection-associated cytokine storm. Additionally, the EGYVIR extract has an in vitro virucidal effect for SARS-CoV-2. The in vitro study of EGYVIR extract against SARS-CoV-2 on Huh-7 cell lines, revealed the potential role of NF-kβ/TNFα/IL-6 during the infection process. EGYVIR antagonizes the NF-kβ pathway in-silico and in-vitro studies. Consequently, it has the potential to hinder the release of IL-6 and TNFα, decreasing the production of essential cytokines storm elements.
Type of Medium:
Online Resource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0241739
DOI:
10.1371/journal.pone.0241739.g001
DOI:
10.1371/journal.pone.0241739.g002
DOI:
10.1371/journal.pone.0241739.g003
DOI:
10.1371/journal.pone.0241739.g004
DOI:
10.1371/journal.pone.0241739.g005
DOI:
10.1371/journal.pone.0241739.g006
DOI:
10.1371/journal.pone.0241739.g007
DOI:
10.1371/journal.pone.0241739.g008
DOI:
10.1371/journal.pone.0241739.g009
DOI:
10.1371/journal.pone.0241739.t001
DOI:
10.1371/journal.pone.0241739.t002
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2020
detail.hit.zdb_id:
2267670-3